Status: Recruiting
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.
Participants needed: 12
Trial details
Phase: Phase 3Age: 0-1Biological sex: AllType: InterventionalSponsor: Inozyme PharmaUpdated: Mar 18, 2026Locations: 8
Eligibility criteria
Infant aged ≤ 1 year at the time of enrollment. [+4]
Receiving end-of-life or hospice care. [+3]